Publicación:
Perspectiva actual en manejo de Arritmias en Cardiomiopatía Chagásica

dc.contributor.authorArellano , Alyi Alejandrospa
dc.contributor.authorCastilla, Sofia Marinaspa
dc.contributor.authorOrtiz, Eduerspa
dc.contributor.authorLozano, Tatianaspa
dc.date.accessioned2022-07-15 00:00:00
dc.date.available2022-07-15 00:00:00
dc.date.issued2022-07-15
dc.description.abstractIntroducción: la enfermedad de Chagas es un problema de salud pública en América Latina y las arritmias ventriculares son las complicaciones más frecuentes, es por esto por lo que se hace crucial conocer su abordaje terapéutico. La enfermedad de Chagas representa un impacto mayor a la salud debido a que suele presentarse en poblaciones con dificultades al acceso a los servicios de salud. La aparición de arritmias es una situación común en estos pacientes con afectación cardiaca. Objetivo: elaborar una revisión narrativa sobre los diferentes manejos terapéuticos utilizados actualmente en los pacientes con cardiomiopatía Chagásica que padecen arritmias ventriculares. Métodos: se realizó una revisión general de la literatura mediante la búsqueda de artículos en varias bases de datos. Se encontró en la búsqueda inicial 14.400 artículos y finalmente se incluyeron 17 en la revisión. Resultados: la cardiomiopatía Chagásica es la complicación más frecuente de la infección por el T. Cruzi donde una de sus presentaciones clínicas iniciales es la aparición de arritmias y la explicación más aceptada actualmente sobre su fisiopatología la divide en cuatro tipos de alteraciones: microvascular, disautonomía, mecanismo inmunológico por autoanticuerpos y daño miocárdico directamente relacionado con la persistencia del parásito en el tejido. Conclusión: el tratamiento médico farmacológico y no farmacológico ha dado resultados positivos, pero todavía hace falta evidencia sobre las repercusiones a largo plazo.spa
dc.description.abstractIntroduction: Chagas disease is a public health problem in Latin America and ventricular arrhythmias are the most frequent complications, which is why it is crucial to know its therapeutic approach. Chagas disease represents a major health impact due to the fact that it usually occurs in populations with difficult access to health services. The appearance of arrhythmias is a common situation in these patients with cardiac involvement. Objective: to review the different therapeutic approaches currently used in patients with Chagasic cardiomyopathy who suffer ventricular arrhythmias. Methods: a general review of the literature was carried out by searching for articles in several databases. We found 14,400 articles in the initial search and finally 17 were included in the review. Results: Chagasic cardiomyopathy is the most frequent complication of T. Cruzi infection where one of its initial clinical presentations is the appearance of arrhythmias and the currently most accepted explanation of its pathophysiology divides it into four types of alterations: microvascular, dysautonomia, mechanism immune by autoantibodies and myocardial damage directly related to the persistence of the parasite in the tissue. Conclusions: pharmacological and non-pharmacological medical treatment has yielded positive results, but evidence on long-term repercussions is still lacking.eng
dc.format.mimetypeapplication/pdfspa
dc.identifier.doi10.32997/rcb-2022-4061
dc.identifier.eissn2389-7252
dc.identifier.issn2215-7840
dc.identifier.urlhttps://doi.org/10.32997/rcb-2022-4061
dc.language.isospaspa
dc.publisherUniversidad de Cartagenaspa
dc.relation.bitstreamhttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/4061/3261
dc.relation.citationeditionNúm. 3 , Año 2022spa
dc.relation.citationendpage222
dc.relation.citationissue3spa
dc.relation.citationstartpage211
dc.relation.citationvolume11spa
dc.relation.ispartofjournalRevista Ciencias Biomédicasspa
dc.relation.referencesPérez-Molina JA, Molina I. Chagas disease. Lancet. 2018 Jan 6;391(10115):82-94. doi: 10.1016/S0140-6736(17)31612-4. Epub 2017 Jun 30. PMID: 28673423.spa
dc.relation.referencesMalik LH, Singh GD, Amsterdam EA. Chagas Heart Disease: An Update. Am J Med. 2015 Nov;128(11): 1251.e7-9. doi: 10.1016/j.amjmed.2015.04.036. Epub 2015 Jun 4. PMID: 26052027.spa
dc.relation.referencesSchmunis GA, Yadon ZE. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop. 2010 jul-Aug;115(1-2):14-21. DOI: 10.1016/j.actatropica.2009.11.003. Epub 2009 Nov 20. PMID: 19932071.spa
dc.relation.referencesTeixeira AR, Nitz N, Guimaro MC, Gomes C, Santos-Buch, CA. Chagas disease. Postgraduate medical journal. 2006; 82(974), 788–798. https://doi.org/10.1136/pgmj.2006.047357.spa
dc.relation.referencesBern C. Chagas’ Disease. New England Journal of Medicine. 2015; 373(5), 456–466. DOI:10.1056/nejmra1410150. PMID: 26222561.spa
dc.relation.referencesPalmezano Díaz JM, Plazas Rey LK, Rivera Castillo KEs, Rueda Rojas VP. Chagas disease: reality of a frequent pathology in Santander, Colombia. Medical UIS. 2015; 28(1), 81-90. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-03192015000100008&lng=en&tlng=esspa
dc.relation.referencesCarmo Rassi D, Tiemi Hotta V, Gomes Furtado R, Campos Vieira ML, Paula Turco F, Henrique Melato L, Godoy Nunes C, Rassi L, Rassi S. Incidence and variables associated with arrhythmias during dobutamine-atropine stress echocardiography among patients with Chagas disease. Echocardiography. Mount Kisco, N.Y. 2019; 36(7), 1338–1345. DOI: https://doi.org/10.1111/echo.14341spa
dc.relation.referencesCianciulli TF, Albarracín GA, Napoli Llobera M, Prado NG, Saccheri MC, Hernández Vásquez YM, Méndez RJ, Beck MA, Baez KG, Balletti LR. Speckle tracking echocardiography in the indeterminate form of Chagas disease. Echocardiography. Mount Kisco, N.Y. 2021; 38(1), 39–46. DOI: 10.1111/echo.14917spa
dc.relation.referencesEcheverría, L.E., Rojas, L.Z., Rueda-Ochoa, O.L. et al. Longitudinal strain by speckle tracking and echocardiographic parameters as predictors of adverse cardiovascular outcomes in chronic Chagas cardiomyopathy. Int J Cardiovasc Imaging (2022). https://doi.org/10.1007/s10554-021-02508-5spa
dc.relation.referencesCésar E. Barrera-Avellaneda, Manuel A. Paz, Jaime F. Salazar-Niño, Utilidad del “speckle tracking” en pacientes no oncológicos, Revista Colombiana de Cardiología, Volume 26, Supplement 1, 2019, Pages 91-102, ISSN 0120-5633,https://doi.org/10.1016/j.rccar.2018.10.017.(https://www.sciencedirect.com/science/article/pii/S0120563319300427spa
dc.relation.referencesBocchi EA, Bestetti RB, Scanavacca MI, Cunha Neto E, Issa VS. Chronic Chagas Heart Disease Management: From Etiology to Cardiomyopathy Treatment. Journal of the American College of Cardiology. 2017; 70(12), 1510–1524. DOI: https://doi.org/10.1016/J.JACC.2017.08.004spa
dc.relation.referencesSalazar WE. Update on the management of Chagas disease. Rev.méd. sinerg. [Internet]. 2019 Nov 1 [cited 2021 Dec 28];4(11): e291. DOI: https://doi.org/10.31434/rms.v4i11.291spa
dc.relation.referencesKirchhoff L.V., & Rassi A, Jr. (2019). Enfermedad de chagas y tripanosomosis. Kasper D, & Fauci A, & Hauser S, & Longo D, & Jameson J, & Loscalzo J(Eds.), Harrison. Principios de Medicina Interna, 19e. McGraw Hill.spa
dc.relation.referencesMarin-Neto JA, Cunha-Neto E, Maciel B, Simões M. Pathogenesis of Chronic Chagas Heart Disease. Circulation. 2007; 115:1109–1123. DOI: https://doi.org/10.1161/CIRCULATIONAHA.106.624296spa
dc.relation.referencesBenaim G, Paniz Mondolfi A. The emerging role of amiodarone and dronedarone in Chagas disease. Nature Reviews Cardiology. 2012; 9(10), 605–609. DOI: 10.1038/nrcardio.2012.108.spa
dc.relation.referencesStein C, Migliavaca CB, Colpani V, Rosa PRd, Sganzerla D, et al. Amiodarone for arrhythmia in patients with Chagas disease: A systematic review and individual patient data meta-analysis. PLOS Neglected Tropical Diseases. 2018; 12(8): e0006742. https://doi.org/10.1371/journal.pntd.0006742.spa
dc.relation.referencesCastro RRT, Porphirio G, Xavier SS, Moraes RS, Ferlin EL, Ribeiro JP, da Nóbrega ACL. Cholinesterase inhibition reduces arrhythmias in asymptomatic Chagas disease. Cardiovasc Ther. 2017 Oct;35(5). doi: 10.1111/1755-5922.12288. PMID: 28715142.spa
dc.relation.referencesTomaz Barbosa MP, da Costa Rocha MO, Barbosa de Oliveira A, Lombardi F, Pinho Ribeiro AL. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease. EP Europace. 2013; Volumen 15, Número 7, Páginas 957 - 962, doi: 10.1093/europace/eut011spa
dc.relation.referencesGali W, Sarabanda A, Baggio J, Ferreira L, Gomes G, Marin-Neto JA, Junqueira L. Implantable cardioverter-defibrillators for the treatment of sustained ventricular arrhythmias in patients with Chagas heart disease: comparison with a control group treated with amiodarone alone, Europace EP. 2014; volume 16, number 5, pages 674–680. DOI: https://doi.org/10.1093/europace/eut422.spa
dc.relation.referencesRassi FM, Minohara L, Rassi A Jr, Correia LCL, Marin-Neto JA, Rassi A, da Silva Menezes A Jr. Systematic Review and Meta-Analysis of Clinical Outcome After Implantable Cardioverter-Defibrillator Therapy in Patients With Chagas Heart Disease. JACC Clin Electrophysiol. 2019 Oct;5(10):1213-1223. DOI: 10.1016/j.jacep.2019.07.003. Epub 2019 Aug 28. PMID: 31648747.spa
dc.relation.referencesMartinelli M, de Siqueira SF, Sternick EB, Rassi A Jr, Costa R, Ramires JA, Kalil Filho R. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease. Am J Cardiol. 2012 Oct 1;110(7):1040-5. DOI: 10.1016/j.amjcard.2012.05.040. Epub 2012 Jun 20. PMID: 22727179.spa
dc.relation.referencesRomero J, Velasco A, Pisani CF, Alviz I, Briceno D, Díaz JC, Di Biase L. Advanced Therapies for Ventricular Arrhythmias in Patients with Chagasic Cardiomyopathy. Journal of the American College of Cardiology, 2021; 77(9), 1225–1242. DOI: 10.1016/j.jacc.2020.12.056.spa
dc.relation.referencesPisani CF, Romero J, Lara S, Hardy C, Chokr M, Sacilotto L, Wu TC, Darrieux F, Hachul D, Kalil-Filho R, Di Biase L, Scanavacca M. Efficacy and safety of combined endocardial/epicardial catheter ablation for ventricular tachycardia in Chagas disease: A randomized controlled study. Heart Rhythm. 2020 Sep;17(9):1510-1518. doi: 10.1016/j.hrthm.2020.02.009. Epub 2020 Feb 20. PMID: 32087356spa
dc.relation.referencesRomero J., Shivkumar K., Di Biase L., et al. "Dominando el arte del acceso epicárdico en electrofisiología cardíaca”. Ritmo cardíaco 2019; 16:1738-1749spa
dc.relation.referencesTarrado X, Sarquella-Brugada G, Saura L, Manzanares A, Julià V, Ribó JM. Left cardiac sympathetic denervation in congenital ventricular arrhythmias: initial experience [Left cardiac sympathetic denervation in congenital ventricular arrhythmias: initial experience]. Cir Pediatr. 2014 15 de abril; 27 (2): 98-101. Español. PMID: 27775280.spa
dc.relation.referencesSáenz LC, Corrales FM, Bautista W, Traina M, Meymandi S, Rodriguez DA, Tellez LJ, Vaseghi M, Garcia F, Shivkumar K, Bradfield JS. Cardiac sympathetic denervation for intractable ventricular arrhythmias in Chagas disease. Heart Rhythm. 2016; Jul;13(7):1388-94. DOI: 10.1016/j.hrthm.2016.03.014. Epub 2016 Mar 9. PMID: 26969783.spa
dc.relation.referencesMalavassi F, Rodríguez D, García F, Sáenz L. Bilateral cervicothoracic sympathectomy as treatment of refractory ventricular arrhythmias. Academic Record. 2019; 59(Noviembre), 127-134. Recovered from http://revista.uaca.ac.cr/index.php/actas/article/view/146spa
dc.relation.referencesAkinseye OA, Ralston WF, Johnson KC, Ketron LL, Womack CR, Ibebuogu UN. Renal Sympathetic Denervation: A Comprehensive Review. Current Problems in Cardiology. 2021; 46(3), 100598. DOI: 10.1016/j.cpcardiol.2020.1005spa
dc.relation.referencesHawson J, Harmer JA, Cowan M, Virk S, Campbell T, Bennett RG, Anderson RD, Kalman J, Lee G, Kumar S. Renal Denervation for the Management of Refractory Ventricular Arrhythmias: A Systematic Review. JACC Clin Electrophysiol. 2021 Jan;7(1):100-108. DOI: 10.1016/j.jacep.2020.07.019. Epub 2020 Sep 30. PMID: 33478701.spa
dc.relation.referencesRemo BF, Preminger M, Bradfield J, Mittal S, Boyle N, Gupta A, Shivkumar K, Steinberg JS, Dickfeld T. Safety and efficacy of renal denervation as a novel treatment of ventricular tachycardia storm in patients with cardiomyopathy. Heart Rhythm. 2014 Apr;11(4):541-6. DOI: 10.1016/j.hrthm.2013.12.038. Epub 2013 Dec 31. PMID: 24389229; PMCID: PMC4253025.spa
dc.relation.referencesSpadaro AG, Bocchi EA, Souza GE, et al. Renal denervation in patients with heart failure secondary to Chagas' disease: A pilot randomized controlled trial. Catheter Cardiovasc Interv. 2019;1–7. DOI: https://doi.org/10. 1002/ccd.28393.spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.creativecommonsEsta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0spa
dc.sourcehttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/4061spa
dc.subjectChagas diseaseeng
dc.subjectcardiomyopathy chagasiceng
dc.subjectarrhythmiaeng
dc.subjectantiarrhythmic drugseng
dc.subjectsympathetic denervationeng
dc.subjectEnfermedad de Chagasspa
dc.subjectcardiomiopatía Chagásicaspa
dc.subjectarritmiaspa
dc.subjectantiarrítmicosspa
dc.subjectdenervación simpáticaspa
dc.titlePerspectiva actual en manejo de Arritmias en Cardiomiopatía Chagásicaspa
dc.title.translatedCurrent perspective on Arrhythmia management in Chagasic Cardiomyopathyeng
dc.typeArtículo de revistaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.coarhttp://purl.org/coar/resource_type/c_dcae04bcspa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.localJournal articleeng
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTREVspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dspace.entity.typePublication

Archivos

Datos de Contacto

Imagen Escudo Universidad de Cartagena

 

 

 

Línea de Atención

Línea Anticorrupción

Síguenos en: